

Pharmaceuticals & Medical Devices Bureau of India  
Balance Sheet As At 31 March, 2023

Particulars	Notes no.	As at	As at
		31 March, 2023	31 March, 2022
		Amount in Rs.	Amount in Rs.
<b>I Trust funds / corpus</b>			
Contribution of CPSUs	1	75,00,000	75,00,000
<b>Reserve and Surplus</b>	2	5,29,37,77,396	3,51,39,94,252
<b>Current liabilities</b>			
Trade payables	3	1,12,84,47,917	1,01,85,33,234
Others liabilities	4	1,71,83,35,233	1,12,52,97,281
<b>Total</b>		<b>8,14,80,60,546</b>	<b>5,66,53,24,767</b>
<b>II Assets</b>			
<b>Non-current assets</b>			
Fixed assets	5		
(I) Tangible assets		1,30,22,437	84,00,613
(II) Intangible assets		36,02,542	5,39,349
<b>Current assets</b>			
Inventories	6	2,61,29,88,025	1,46,46,17,229
Trade receivables	7	1,48,51,35,279	1,19,75,44,395
Cash and cash equivalents	8	2,42,34,66,703	2,67,26,89,034
Short-term loans and advances	9	87,07,02,719	1,15,96,840
Other current assets	10	73,91,42,841	30,99,37,306
<b>Total</b>		<b>8,14,80,60,546</b>	<b>5,66,53,24,767</b>
<b>III Accompanying Notes Forming Part of Financial Statements</b>	1 - 36		

As per our report of even date  
For APRA and Associates LLP  
Chartered Accountants  
(Firm Registration No.: 011078N/N500064)

For Pharmaceuticals & Medical Devices Bureau of India

Sd/-  
Arun Kumar Gupta  
Designated Partner  
Membership No.: 089657

Sd/-  
General Manager (F & A)

Sd/-  
CEO & Secretary General

Place: New Delhi  
Date: 27-09-2023

Pharmaceuticals & Medical Devices Bureau of India  
Statement Of Profit And Loss For The Year Ended 31 March 2023

Particulars	Notes	No	Year ended	Year ended
			31 March, 2023	31 March, 2022
			Amount in Rs.	Amount in Rs.
Revenue from operations	11		7,90,11,52,502	5,67,57,93,922
Other income	12		47,88,29,229	26,74,81,397
Grant in Aid (General)			1,00,00,00,000	68,50,00,000
<b>I Total revenue</b>			<b>9,37,99,81,731</b>	<b>6,62,82,75,319</b>
<b>Expenses:</b>				
Cost of goods purchased	13		6,65,17,65,771	4,56,74,12,930
Change in inventories (finished goods)	14		(1,14,83,70,796)	(41,40,81,701)
Employee benefit expenses	15		9,29,11,156	7,63,49,427
Finance cost	16		2,59,143	70,255
Depreciation and amortization expense	5		44,17,277	21,20,806
Other expenses	17		1,40,62,73,314	1,20,97,88,835
<b>II Total expenses</b>			<b>7,00,72,55,865</b>	<b>5,44,16,60,552</b>
<b>III Profit /(Loss) before tax ( I-II )</b>			<b>2,37,27,25,866</b>	<b>1,18,66,14,767</b>
<b>IV Current Tax</b>			59,29,42,721	21,85,29,720
<b>V Profit /(Loss) Carried forward to BS ( III-IV)</b>			<b>1,77,97,83,145</b>	<b>96,80,85,047</b>

Accompanying Notes Forming Part of 1 - 35  
Financial Statements

As per our report of even date  
For APRA and Associates LLP  
Chartered Accountants  
(Firm Registration No.: 011078N/N500064)

For Pharmaceuticals & Medical Devices Bureau of India

Sd/-

Arun Kumar Gupta  
Designated Partner  
Membership No.: 089657

Place: New Delhi  
Date: 27-09-2023

Sd/-

General Manager (F & A)

Sd/-

CEO & Secretary General